UBS analyst Xian Deng upgraded Argenx to Buy from Neutral on August 26, with a price target of $1,400 per share, citing peak sales potential of $20 billion for the company's autoimmune therapy Vyvgart.
The upgrade is based on Deng's confidence in Vyvgart's addressable market. The drug, which Argenx markets for generalized myasthenia gravis and other autoimmune conditions, has shown efficacy in patient populations historically underserved by existing therapies. A $20 billion peak sales forecast would position Vyvgart among the largest-revenue drugs in the sector if realized.
Argenx is a Belgium-based biopharmaceutical company focused on immunology. Vyvgart, a neonatal Fc receptor antagonist, was approved by the FDA for generalized myasthenia gravis in 2023 and has since expanded into additional autoimmune indications. The company has reported that the drug is available in multiple markets, though the majority of its near-term revenue is expected to come from North America.
Deng's prior Neutral rating had constrained the stock's institutional appeal during a period when autoimmune therapies faced mixed trading patterns. The upgrade removes that constraint and provides equity research coverage aligned with the company's own commercial guidance for Vyvgart's expansion.
UBS's $20 billion peak sales estimate is among the highest on the Street for the drug. Peer institutions have modeled lower peaks, typically in the $12 billion to $15 billion range, based on penetration assumptions and competitive dynamics in the generalized myasthenia gravis and related autoimmune markets. Deng's forecast assumes higher market adoption than the consensus baseline.
Argenx trades on Nasdaq under ticker ARGX. The stock has been volatile, driven by clinical trial readouts and commercial execution data for Vyvgart across its indications. The company also has a pipeline of earlier-stage programs in immunology, though Vyvgart remains the primary revenue driver in its near-term financial model.
UBS's target price of $1,400 implies material upside from current levels if the peak sales thesis holds and the company achieves profitability commensurate with that revenue base. The analyst's upgrade places the burden of proof on Argenx to continue expanding Vyvgart's label and market penetration without eroding pricing power in competitive markets.
